Vaccine Types and Platforms
Vaccine types and platforms describe the different technological strategies used to present an antigen to the immune system so that it builds protective, recallable immunity without causing the disease itself. The major families range from classical preparations made from whole pathogens (live attenuated and inactivated) to defined-component and genetically encoded approaches (recombinant and subunit, mRNA, and viral-vector vaccines), each with a characteristic balance of immunogenicity, safety, stability, and manufacturing demands.
Definition
A vaccine platform is the underlying technological approach used to deliver or encode an antigen so as to elicit a protective adaptive immune response; vaccine types are the resulting categories of product distinguished by the form in which that antigen is presented.
Scope
This area orients the reader to how vaccines are categorised by platform and why platform choice matters. It links to the principal topic families covered here and explains the shared logic that connects them; it does not provide schedules, dosing, or individual immunisation advice, which belong to clinical practice and official guidance.
Sub-topics
Core questions
- What form does the antigen take in each platform, and how does the immune system encounter it?
- How do platforms differ in immunogenicity, the need for adjuvants or boosters, and the breadth of the response they elicit?
- What trade-offs in safety, stability, cold-chain requirements, and manufacturing scalability distinguish the platforms?
- How is protection from each platform measured and corroborated through correlates of protection?
Key concepts
- Antigen presentation
- Immunogenicity
- Adaptive immune memory
- Correlates of protection
- Adjuvants
- Live versus non-live preparations
- Antigen-encoding (nucleic-acid and vectored) platforms
- Manufacturing scalability and cold chain
Mechanisms
Across platforms the common goal is to expose the immune system to a pathogen-derived antigen in a form that triggers durable adaptive memory while avoiding disease. Live attenuated vaccines replicate transiently and broadly mimic natural infection; inactivated and subunit preparations present non-replicating antigen, often needing adjuvants or boosters; nucleic-acid and viral-vector platforms instead deliver genetic instructions so the recipient's own cells transiently express the antigen, which favours both antibody and T-cell responses. Whichever route is used, success is judged against immunological correlates of protection, the measurable immune markers that track with clinical efficacy.
Clinical relevance
Understanding vaccine platforms helps clinicians and learners interpret why products differ in their immune responses, storage needs, and contraindication profiles, and why some platforms are preferred in particular populations or outbreak settings. This entry is a reference orientation to platform concepts; it describes how vaccines are designed and is not a basis for individual immunisation decisions, which follow current schedules and official guidance.
Evidence & guidelines
The comparative properties of platforms are synthesised in vaccinology reviews and reference texts, and platform-level differences in antigen presentation became especially visible during the COVID-19 pandemic, when mRNA, viral-vector, inactivated, and subunit products were deployed in parallel. Platform-specific clinical recommendations are set by national immunisation programmes and bodies such as the World Health Organization and national advisory committees.
History
Vaccinology progressed from whole-pathogen approaches pioneered in the eighteenth and nineteenth centuries, through inactivated and live attenuated vaccines refined across the twentieth century, to recombinant subunit vaccines from the 1980s and, most recently, nucleic-acid and viral-vector platforms that reached large-scale human use during the COVID-19 pandemic. Each wave broadened the toolbox of how an antigen can be presented.
Key figures
- Stanley Plotkin
- Rino Rappuoli
- Andrew Pollard
Related topics
Seminal works
- plotkin-2010
- rappuoli-2014
- pollard-bijker-2021
Frequently asked questions
- What distinguishes one vaccine platform from another?
- Platforms differ in the form in which the antigen is delivered, whether a whole pathogen, a purified component, or genetic instructions for the body to make the antigen, which in turn shapes immunogenicity, safety, stability, and manufacturing requirements.
- Is one platform always better than the others?
- No. Each platform carries trade-offs in the strength and breadth of the immune response, storage and cold-chain needs, speed of manufacture, and suitability for particular populations, so the best choice depends on the target disease and setting.